Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (211-220 of 228) with videos related to

Pageof 23
Sort By:
Neuro-Oncology|July 4, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Geburtshilfe Und Frauenheilkunde|June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast CancerRachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Cancer Communications (London, England)|January 6, 2025
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXdChristian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Cancers|September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast CancerDiana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 1 - Early Stage Breast CancerAndreas D Hartkopf, Tanja N Fehm, Manfred Welslau, et al.
Pageof 23

Showing results (211-220 of 228) with videos related to

Sort By:
Pageof 23
Neuro-Oncology|July 4, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Geburtshilfe Und Frauenheilkunde|June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast CancerRachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Cancer Communications (London, England)|January 6, 2025
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXdChristian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Cancers|September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast CancerDiana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 1 - Early Stage Breast CancerAndreas D Hartkopf, Tanja N Fehm, Manfred Welslau, et al.
Pageof 23